Misoprostol: New frontiers; benefits beyond the gastrointestinal tract

Scandinavian Journal of Rheumatology

Volumn 21, Issue S92, 1992, Pages 31-52

  Shield, M J ^a  

^a Searle Bucks ^*  (United Kingdom)

Author keywords

Arthritis; Chondroprotection; Homeostasis; IL 1; Misoprostol; NSAID; Synergy; Triggering

Indexed keywords

ACETYLSALICYLIC ACID; AZAPROPAZONE; CHONDROPROTECTIVE AGENT; CYCLOSPORIN; DEXAMETHASONE; DICLOFENAC; ENDOTOXIN; ENPROSTIL; IBUPROFEN; ICOSANOID; INDOMETACIN; INTERLEUKIN 1; METHYLPREDNISOLONE; MISOPROSTOL; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE; PROTECTIVE AGENT; SALICYLATE SODIUM; TUMOR NECROSIS FACTOR; IMMUNOLOGICAL ADJUVANT;

ANALGESIC ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTHRITIS; CELL PROTECTION; CONFERENCE PAPER; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; PRIORITY JOURNAL; BONE DISEASE; CARTILAGE; DRUG EFFECT; KIDNEY; PAIN; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ARTHRITIS; BONE DISEASES; CARTILAGE; HOMEOSTASIS; HUMAN; KIDNEY; MISOPROSTOL; PAIN;

EID: 0026466675     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749209101387     Document Type: Article

References (70)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. Effect of prostaglandin E1 on adjuvant arthritis
3. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid
4. Gamma linolenic acid. Reviews in Contmporary Pharmacotherapy
5. Prostaglandin E1: Physiological significance and clinical use
6. Effects of essential fatty acids on prostaglandin biosynthesis
7. The metabolism of diho-mogammalinolenic acid in man
8. Dietary fatty acids, prostaglandin endoperoxides and the prevention of thrombosis
9. Metabolism of arachidonic acid by platelets: Utilization of arachidonic acid by human platelets in presence of linoleic and dihomogammalinolenic acid
10. Basal levels of human platelet prostaglandins:PGE 1 is more elevated than PGE2
11. Cyclic AMP induces synthesis of prostaglandin E1 in platelets
12. The effect of DCLA on platelet aggregation and prostaglandin release, erythrocyte membrane fatty acids and serum lipids: Evidence for defects in PGE1 synthesis and d5-desaturase activity in insulin-dependent diabetics
13. A chemotactic role for prostaglandins released from polymorphonuclear cells during phagocytosis
14. Quantitative analysis of prostaglandins in cell culture medium by high resolution gas chromatography with electron capture detection
15. Separation and quantification of prostaglandins E1 and E2 as their paracyl derivatives using reverse phase high pressure liquid chromatography
16. Adrenergic stimulation modifies prostaglandin synthesis by rat vas deferens
17. Metabolic factors regulating the generation of prostaglandins E1 and E2 by isolated rat uterus
18. Effects of cortisone, hydrocortisone and prostaglandin fatty acid precursors on the spontaneous motility of the uterus isolated from ovariectomized rats
19. Studies on fatty acid metabolism in liver diseases. Effects on linoleate and gammalinolenate on the synthesis of arachidonate and the prevention of fatty liver in the carbon tetrachloride injured rat liver
20. Reduced levels of prostaglandin precursors in the blood of atopic patients: Defective delta 6 desaturase function as a biochemical basis for atrophy
21. Prostaglandin E1 in normal human skin: Methodological evaluation, topographical distribution and data related to sex and age
22. Characterization of PGE2 receptors mediating increased vascular permeability in inflammation
23. Anti-PGE antibodies inhibit in-vivo development of cell-mediated immunity
24. Prostaglandins and cell-mediated immunity
25. Modulation of in vivo immune responses following changcs in the intake of csscntial fatty acids
26. Nutrition and immunity: The immunoregulatory effect of n-6 essential fatty acids is mediated through PGE
27. Inhibitory effect of non-steroidal inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing
28. Role of interleukin 1 in inflammatory bowel disease—enhanced production during active disease
29. Renin. an-giotensin, kinins, prostaglandins and leukotrienes
30. Feedback responses during sequential inhibition of angiotensin and thromboxane
31. Effect of oral prostaglandin in indomethacin induced renal dysfunction in alcoholic cirrhosis: A double-blind randomized study
32. Does cyclosporine inhibit renal prostaglandin synthesis?
33. Effects of the prostaglandin E1 analog misoprostol on cyclosporine nephrotoxicity
34. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisonc
35. Multicentre study in the United Kingdom to examine the effects of misoprostol as adjunctive therapy in reducing the incidence of renal transplant rejection
36. Immunosuppressive effect of misoprostol—a new synthetic prostaglandin E1 analogue
37. The immunosuppressive properties of new prostaglandin E1 analogs
38. Evaluation of the effects of misoprostol on immunologic competence in normal volunteers
39. Oral prostaglandin E1 analog misoprostol reduces renal ischemic injury
40. Effect of cyclic AMP on release of lysosomal enzymes from phagocytes
41. Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes
42. Aspirin
43. The mechanisms of action of non-steroidal anti-inflammatory drugs
44. Evidence that misoprostol free acid mediates the inhibitory activity of misoprostol on human neutrophil superoxide production: Involvement of a subtype prostaglandin E receptor
45. Initial kinetics of lysosomal enzyme secretion and superoxide anion generation by human polymorphonuclear leukocytes
46. Guanine nucleotides modulate the binding affinity of the oligopeptide chemoattractant receptor on human polymorphonuclear leukocytes
47. Demonstration of specific E-type prostaglandin receptors using enriched preparations of canine parietal cells and tritiated misoprostol free acid
48. Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): Disorders of essential fatty acid (EFA) metabolism
49. Synthesis of estradiol fatty acid esters by human breast tumours: Fatty acid composition and comparison to estrogen and progesterone receptor content
50. Effect of misoprostol on concentrations of prostaglandins in synovial fluid
51. Prevention of gastric mucosal damage in live E. coli shock by pretreatment with misoprostol. (Report of poster at 1985 AGA entitled “stress ulcer prevention in live E. coii sepsis in cats”.)
52. Misoprostol augments the anti-inflammatory activity of non-steroid. corticosteroid and antioxidant drugs in rats
53. Peripheral mechanisms contributing to hyper-algcsic pain
54. Presentation to American Pain Symposium, Oct. 25-29, 1991
55. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist
56. Protective effects of aspirin in endotoxic shock
57. Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction
58. Misoprostol clinical pharmacology, establishment of activity in man
59. Effects of misoprostol on human circulation
60. Prostaglandin E1: Is it useful? (Editorial)
61. Cartilage damage and repair: The roles of IL-1, NSAIDs, and prostaglandins in osteoarthritis
62. The sensitivity of synthesis of human cartilage matrix to inhibition by IL-1 suggests a mechanism for the development of osteoarthritis
63. Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate
64. Inhibitory effects of diclofenac and indomethacin on interleukin-1 induced changes in PGE2 release. A novel effect on free arachidonic acid levels in human synovial cells
65. Effect on non-steroidal anti-inflammatory drugs on the course of osteoarthritis
66. Cartilage maintenance in osteoarthritis: Interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair
67. The interactions of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair
68. Misoprostol does not protect articular cartilage from salicylate-induced suppression of proteoglycan synthesis
69. Vivo studies of cartilage regeneration after damage induced by catabolin-interleukin-1